Compare RDNW & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNW | GLSI |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.8M | 254.7M |
| IPO Year | 2014 | 2020 |
| Metric | RDNW | GLSI |
|---|---|---|
| Price | $4.93 | $15.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $57.00 |
| AVG Volume (30 Days) | 61.8K | ★ 131.6K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.84 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | N/A |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $80.17 | ★ N/A |
| Revenue Growth | ★ 91.10 | N/A |
| 52 Week Low | $3.20 | $7.78 |
| 52 Week High | $8.55 | $34.10 |
| Indicator | RDNW | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 43.70 |
| Support Level | $4.60 | $14.57 |
| Resistance Level | $7.14 | $19.97 |
| Average True Range (ATR) | 0.37 | 1.50 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 15.49 | 27.43 |
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.